Clinical trial shows longer survival and reduced toxicity after CD19 CAR T-cell therapy in low-burden acute lymphoblastic leukemia, highlighting the benefit of earlier treatment.
In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).
No takes yet. Share an insight, caveat, or question.
Park et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: